Our mission is to be the leading provider of equity research in healthcare and life sciences

We produce institutional­ quality equity research on small/mid­cap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.

research-clients

14

Research Clients

reports-published

101

Reports published

readers-in-database

10k+

Readers in database

Read our @HChiMed Update note covering #Elunate commercial progress to date, highlighting upcoming #savolitinib #NSCLC data at #aacr2019 , & our updated estimates post-FY18 $HCM $HCM.L https://t.co/WrQb4WeQhK

Read our note on @NexstimOyj as it looks to securing the commercial future of NBT in depression at https://t.co/qQmPY3Dxtz

We highlight that @HChiMed has global development #collaborations for PD-1 combos with Innovent (Tyvyt) for #fruquintinib and Junshi (Tuoyi) for #surufatinib $HCM

.@HChiMed's wholly owned #VEGFR inhibitor #surufatinib features in the latest @TheLancetOncol

Interim Phase III data from the #China SANET-p and SANET-ep trials in NET (#neuroendcrine tumours) are expected later in 2019 $HCM

The timeline for the next China #NDRL update are clearer, with potential for inclusion of @LillyPad and @HChiMed's cancer drug #Elunate (#fruquintinib) this year $HCM

US portfolio expansion underway as @BONESUPPORT_AB launches the #BONIFY 100% DBM bone graft range at #AAOS2019.

#BONIFY's #osteoinductive properties complement the #osteoconductive #CERAMENT platform. Both products will be sold via $BONEX's direct US distributor network.

Subscribe to our research

Please sign up here to be added to our distribution database